Roche Deal for Flatiron Health Builds its Oncology Muscle

Roche Deal for Flatiron Health Builds its Oncology Muscle

Roche (SIX: RO) couldn’t let a good startup slip away. The Swiss drug maker announced it will pay $1.9 billion to keep New York City-based Flatiron Health, Inc. from going public. When it was founded in 2012, Flatiron’s goal was to gather and analyze data on cancer treatments and sells software based on those insights to help researchers develop drugs more quickly, and with more targeted precision. Toward that end, the company produced an oncology-specific electronic health record (EHR). It currently partners with more than 265 community cancer clinics, six major academic research centers and 14 out of the top 15 therapeutic oncology companies. Roche already holds a 12.6% stake... Read More »